EDIC of National Institute for Diabetes & Endocrinology

03/07/2017

Clinical pharmacy (workshop)

05/03/2017

30/06/2016

The US Food and Drug Administration today approved a new insulin inhaler for use in treating diabetes, its first in years. The product, which is made by California-based MannKind Corporation, uses...

06/04/2016

The use of this drug has been increasing due to its value as a last resort treatment for multi-drug resistant organisms.
http://www.drugs.com/monograph/colistimethate-sodium.html

Colistimethate Sodium reference guide for safe and effective use from the American Society of Health-System Pharmacists (AHFS DI).

21/01/2016

http://www.drugs.com/pro/glycophos-injection.html

Glycophos Injection official prescribing information for healthcare professionals. Includes: indications, dosage, adverse reactions, pharmacology and more.

21/01/2016

http://www.webmd.com/drugs/2/drug-161021/glycophos-intravenous/details

15/01/2016

Annu Rev Neurosci. 2007;30:259-88. Research Support, Non-U.S. Gov't; Review

24/12/2015

Tienam Thrombocytopenia Side Effect Reports
This Thrombocytopenia side effect was reported by a health professional from FR. A 12-year-old patient (weight:NA) experienced the following symptoms/conditions: NA. The patient was prescribed Tienam 500mg/500mg, Poudre Pour Perfusion (dosage: Unk), which was started on May 24, 2013. Concurrently used drugs: •Vancomycin (Unk)
•Zovirax (Unk)
•Cancidas (Unk)
•Fortum (Unk)
•Methotrexate (Unk)
•Cytarabine (Unk)
•Methylprednisolone (Unk)
•Nelarabine (Unk)
When starting to take Tienam 500mg/500mg, Poudre Pour Perfusion the consumer reported the following symptoms: •Agranulocytosis
•Leukopenia
•Thrombocytopenia
The patient was hospitalized. These side effects may potentially be related to Tienam 500mg/500mg, Poudre Pour Perfusion.

24/12/2015

Medications which may cause thrombocytopenia
http://www.globalrph.com/thrombo.htm

19/12/2015

SGLT2 Inhibitor Diabetes Drugs May Cause Ketoacidosis: FDA
he US Food and Drug Administration (FDA) warned today that sodium-glucose cotransporter-2 (SGLT2) inhibitors used to treat type 2 diabetes may lead to ketoacidosis requiring hospitalization.

The warning includes the SGLT2 inhibitors canagliflozin (Invokana, Johnson & Johnson), dapagliflozin (Farxiga, AstraZeneca), and empagliflozin (Jardiance, Lilly/Boehringer), as well as three combination products that include an SGLT2 inhibitor: canagliflozin plus metformin (Invokamet, Johnson & Johnson), dapagliflozin plus metformin extended release (Xigduo XR, AstraZeneca), and empagliflozin plus linagliptin (Glyxambi, Lilly/Boehringer).

A search of the FDA Adverse Event Reporting System database identified 20 cases of acidosis reported as diabetic ketoacidosis (DKA), ketoacidosis, or ketosis in patients treated with SGLT2 inhibitors from March 2013 to June 6, 2014, the FDA said.
http://www.medscape.com/viewarticle/844754

A service unit committed to provide unbiased drug information to health care professionals, patients &/or consumers.

04/08/2015

Q: Of the following which can be used as treatment of calcium channel blockers toxicity?
A) Intravenous calcium
B) Atropine
C) Hyperinsulinemia-euglycemia therapy
D) lipid emulsion therapy
E) All of the above
Answer: E
Mild toxicity of Calcium channel blockers usually resolved with supportive treatment with IVF and transient support with pressors. In case of acute overdose, activated charcoal, gastric lavage, and polyethylene glycol may be used to decontaminate the gut.
In case of severe toxicity, Intravenous calcium can be used. Atropine as well as temporary intravenous pacemaker may be required for un-resolving bradycardia/blocks.
Hyperinsulinemia-euglycemia therapy has been advocated for treatment. Increased insulin mobilizes glucose from peripheral tissues to serve as an alternative fuel source for the heart. Treatment with lipid emulsion therapy has been described too with same mechanism of action.
منقول

02/08/2015

http://www.fda.gov/Drugs/DrugSafety/ucm439484.htm

[03-24-2015] The U.S. Food and Drug Administration (FDA) is warning that serious slowing of the heart rate can occur when the antiarrhythmic drug amiodarone is taken together with either the hepatitis C drug Harvoni (ledipasvir/sofosbuvir) or with Sovaldi (sofosbuvir) in combination with another dir…